aTRX(Oblique Therapeutics)

Basel, 26 April 2023 As expected, significantly lower demand for COVID-19 tests leads to a decrease in Group sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Division sales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, while divisional sales are 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter: US approval of Polivy (first-line treatment for an aggressive form of blood cancer) EU approval of Hemlibra (moderate haemophilia A)Positive phase III data for Vabysmo (retinal vein occlusion, a serious eye disease), Tecentriq plus Avastin (adjuvant therapy for certain forms of liver cancer) and crovalimab (paroxysmal nocturnal haemoglobinuria, a rare blood disease)Positive four-year efficacy and safety data for Evrysdi (spinal muscular atrophy)Launch of new assays to identify clinically relevant mutations in brain cancers Outlook for 2023 confirmed Roche CEO Thomas Schinecker: “We saw strong growth in the first quarter in both divisions’ base business, which largely compensated for the expected drop in sales of COVID-19 tests. We made progress in our pipeline in the first quarter, especially in blood cancer. Besides our recent approvals for our bispecific antibody medicines, Lunsumio and Columvi, we have also just received US approval of Polivy as first-line treatment for an aggressive form of blood cancer. In ophthalmology, Vabysmo, a medicine for severe eye diseases, has shown positive phase III data in retinal vein occlusion. If approved, this would be the third indication for Vabysmo which has already become our strongest growth driver just a year after its launch. We confirm our outlook for 2023.” Sales CHF millions As % of sales % change January‒March 2023 2023 2022 2023 2022 At CER In CHF Group 15,322 16,445 100.0 100.0 -3 -7 Pharmaceuticals Division 11,699 11,159 76.4 67.9 9 5 United States 5,853 5,489 38.2 33.4 6 7 Europe 2,071 2,072 13.5 12.6 5 0 Japan 1,390 1,337 9.1 8.1 18 4 International* 2,385 2,261 15.6 13.8 13 5 Diagnostics Division 3,623 5,286 23.6 32.1 -28 -31 *Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others Outlook for 2023 confirmedDue to the sharp decline in sales of COVID-19 products of roughly CHF 5 billion, Roche expects a decrease in Group sales in the low single digit range (at constant exchange rates). Excluding this COVID-19 sales decline, Roche anticipates solid sales growth in both divisions’ base business. Core earnings per share are targeted to develop broadly in line with the sales decline (at constant exchange rates). Roche expects to further increase its dividend in Swiss francs. Group resultsIn the first three months of the year, Group sales declined by 3% (-7% in CHF) to CHF 15.3 billion. The appreciation of the Swiss franc against most currencies had a negative impact on the results reported in Swiss francs compared to constant exchange rates. As expected, the first quarter 2023 results reflected the exceptionally high demand for COVID-19 tests in the same quarter of 2022, when the Omicron wave was at its peak. Pharmaceuticals Division sales increased markedly by 9% to CHF 11.7 billion, driven by strong global demand for newer medicines to treat severe diseases. The eye medicine Vabysmo, which was only launched in early 2022, became the division’s biggest growth driver. The top five contributors to growth – Vabysmo, Ocrevus (multiple sclerosis), Hemlibra (haemophilia), Evrysdi (spinal muscular atrophy) and Tecentriq (cancer immunotherapy) – generated additional sales of CHF 1.1 billion. The impact of the competition from biosimilars for the established cancer medicines Avastin, Herceptin and MabThera/Rituxan slowed down further (combined approx. CHF 330 million of sales reduction). In the United States, sales increased by 6%. Newer medicines, such as Vabysmo, Ocrevus, Hemlibra and the cancer medicines Tecentriq and Phesgo, were the main contributors. This contrasted with declining sales of Actemra/RoActemra (COVID-19) and of medicines for which patent protection has expired. In Europe, sales were up by 5%. Growth of Evrysdi, Vabysmo, Hemlibra, Phesgo, Ocrevus and other innovative medicines was partially offset by lower Ronapreve (COVID-19) sales and the biosimilars impact. Sales in Japan increased (+18%), mainly due to higher supply of Ronapreve to the government than in the previous year, followed by sales growth of Polivy, Tamiflu (influenza), Vabysmo and Hemlibra. Sales in the International region increased by 13%. The key factors were sales growth of Perjeta, Evrysdi, Tamiflu, Kadcyla and Ocrevus. In China, sales were up 4% due to high demand for Tamiflu, Actemra/RoActemra and Xofluza (influenza), which more than offset the impact of biosimilars. The Diagnostics Division’s base business recorded continued good growth (+4%). Divisional sales were CHF 3.6 billion, down by 28% as sales of COVID-19 tests dropped to CHF 0.3 billion in the first quarter of 2023 from CHF 1.9 billion in the same period last year, when demand was exceptionally high. Immunodiagnostic products, particularly cardiac tests, were the main growth drivers (+9%). Additional growth impulses came from the virology base business (+12%), blood screening (+15%) and diagnostics solutions for the detection and monitoring of cervical cancer (+22%). The decline in sales across all regions is primarily due to the lower demand for COVID-19 tests. The Europe, Middle East and Africa (EMEA) and North America regions decreased by 30% and 39%, respectively. Asia-Pacific fell by 15%; Latin America reported a minus of 8%. Pharmaceuticals: key development milestones in the first quarter of 2023The Pharmaceuticals Division achieved a number of important product development milestones in the first three months of the year, including the US approval of Polivy (aggressive form of blood cancer), the EU approval of Hemlibra (moderate haemophilia A) as well as positive study results on Vabysmo for a serious retinal vascular condition and on crovalimab in PNH, a rare, life-threatening blood condition. Compound Milestone Regulatory HemlibraHaemophilia A EU: label expansion to include moderate haemophilia A Hemlibra, already approved for severe haemophilia A in the EU, will now also provide an effective and convenient prophylactic treatment option for people with moderate haemophilia AModerate haemophilia A can have a significant impact on the lives of people affected, with only 15% living a bleed-free life The approval is based on the results of the HAVEN 6 study, where Hemlibra demonstrated effective bleed control and a favourable safety profile in people with moderate haemophilia A without inhibitors More information: Media Release, 1 February Columvi Blood cancer Columvi (glofitamab) to receive approval in Canada for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Columvi (glofitamab for injection) is the first CD20xCD3 T-cell-engaging bispecific antibody with fixed treatment duration approved in Canada to treat DLBCLAuthorisation is based on results from the phase I/II NP30179 study, which demonstrated Columvi induced durable response rates in people with heavily pre-treated DLBCL More information: local Media Release, 25 March PolivyBlood cancer FDA approves Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin lymphoma in the USPOLARIX trial showed the Polivy combination reduced the risk of disease progression, relapse or death by 27% compared to the standard of care, R-CHOP, with a comparable safety profileFirst-line treatment with Polivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progression More information: Media Release, 20 April Phase III, pivotal and other key readouts CrovalimabHaematology Positive data from global phase III programme for crovalimab in paroxysmal nocturnal haemoglobinuria (PNH), a rare, life-threatening blood condition The COMMODORE 2 study met its co-primary efficacy endpoints, showing that crovalimab achieved disease control in people with PNH who had not been previously treated with complement inhibitorsThe results of the phase III COMMODORE 1 study in people with PNH switching from currently approved C5 inhibitors to crovalimab supported the favourable benefit-risk profile of crovalimab, as seen in the pivotal COMMODORE 2 study Results from both studies will be submitted to regulatory authorities around the world and presented at an upcoming medical meeting More information: Media Release, 7 February VabysmoSevere eye diseases New phase III data show Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO) Vabysmo met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared to afliberceptMore Vabysmo patients displayed an absence of blood vessel leakage in the retina compared to aflibercept patients in a pre-specified exploratory endpoint If approved, RVO would be the third indication for Vabysmo in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular oedema More information: Media Release, 10 February EvrysdiSpinal muscular atrophy New four-year data for Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA) Data from pivotal SUNFISH study showed that increases in motor function observed during the first year were maintained through the fourth year, while the overall rate of adverse events continued to decreaseData confirm long-term efficacy and safety profile of Evrysdi in a broad range of people with type 2 and non-ambulant type 3 SMA More than 8,500 people – from newborns to the over 60s – have been treated with Evrysdi, which is now approved in more than 90 countries worldwide More information: Media Release, 20 March VabysmoSevere eye diseases Roche data highlight strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023 Vabysmo data suggest rapid and robust drying of retinal fluid in patients with neovascular or ‘wet’ age-related macular degeneration and diabetic macular oedemaReal-world data of Vabysmo demonstrate its ability to extend treatment intervals in the first four months while maintaining visual acuityClinical data on an investigational anti-interleukin-6 treatment in uveitic macular oedema will be presented for the first time More information: Media Release, 13 April Tecentriq plus AvastinLiver cancer Tecentriq plus Avastin reduce the risk of cancer returning in people with certain types of liver cancer in a phase III study In the first-ever positive phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%Up to 80% of people with this type of HCC experience disease recurrence, at which point they are faced with poorer prognosis and shorter survivalThese data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 More information: Media Release, 16 April Pharmaceuticals sales Sales CHF millions As % of sales % change January–March 2023 2023 2022 2023 2022 At CER In CHF Pharmaceuticals Division 11,699 11,159 100.0 100.0 9 5 United States 5,853 5,489 50.0 49.2 6 7 Europe 2,071 2,072 17.7 18.7 5 0 Japan 1,390 1,337 11.9 12.0 18 4 International* 2,385 2,261 20.4 20.1 13 5 *Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others Selected top-selling and new medicines Total United States Europe Japan International CHF m % CHF m % CHF m % CHF m % CHF m % OcrevusMultiple sclerosis 1,636 14 1,188 13 298 11 - - 150 32 Perjeta2Breast cancer 1,049 11 392 8 220 1 53 2 384 22 HemlibraHaemophilia A 1,034 24 631 21 206 27 92 24 105 38 TecentriqCancer immunotherapy 920 15 507 14 195 11 105 12 113 34 Actemra/RoActemra2RA, COVID-19 676 -12 296 -22 193 -8 77 - 110 10 RonapreveCOVID-19 567 9 - - - - 567 33 - - Kadcyla2Breast cancer 509 5 198 -3 154 -6 26 -8 131 42 Xolair2Asthma 479 5 479 5 - - - - - - Herceptin2Breast and gastric cancer 477 -17 91 -37 97 -17 9 -30 280 -7 MabThera/Rituxan2Blood cancer, RA 459 -17 274 -21 51 - 6 -13 128 -12 VabysmoEye diseases (nAMD, DME) 432 ** 360 ** 44 - 21 - 7 - Avastin 2Various cancer types 416 -24 133 -25 30 -45 91 -21 162 -19 AlecensaLung cancer 372 9 106 7 73 3 50 5 143 14 EvrysdiSpinal muscular atrophy 363 62 124 13 113 74 21 47 105 189 PhesgoBreast cancer 241 72 98 62 114 59 - - 29 232 Gazyva/Gazyvaro2Blood cancer 197 24 99 32 55 25 8 -35 35 27 Lucentis2Various eye diseases 167 -35 167 -35 - - - - - - PolivyBlood cancer 150 96 46 35 40 93 51 169 13 340 EnspryngNMOSD 54 42 15 16 4 96 33 44 2 246 RozlytrekLung cancer 19 21 10 0 4 80 2 5 3 144 XofluzaInfluenza 18 ** 1 -10 - - - - 17 ** LunsumioBlood cancer 14 - 13 - 2 - - - -1 - SusvimoEye implant 1 -33 1 -33 - - - - - - ** Over 500% DME: diabetic macular oedema / nAMD: neovascular or ‘wet’ age-related macular degeneration / NMOSD: neuromyelitis optica spectrum disorders / RA: rheumatoid arthritis Diagnostics: key milestones in the first quarter of 2023In the first quarter of the year, the Diagnostics Division launched important products in the areas of oncology and virology. Product Milestone Regulatory IDH1 R132H and ATRX antibodiesBrain cancer Launch of two new antibodies to identify clinically relevant mutations in patients with brain cancer Recent advances in cancer genomics have deepened the medical community’s understanding of the molecular alterations in brain tumours, more precisely subclassifying patients into specific diagnosesUnderstanding a patient’s brain tumour mutation status in the IDH1 and ATRX genes enables more informed clinical decisions and may improve patient outcomes The IDH1 R132H and ATRX antibodies are the latest additions to Roche’s neuropathology portfolio, which contains 29 biomarkers More information: Media Release, 23 February VirSNiP SARS-CoV-2 Spike F486PCOVID-19 Launch of COVID-19 PCR test to detect the fast-spreading XBB.1.5 Omicron sub-variant This new test for researchers specifically targets the XBB.1.5 Omicron sub-variant and runs on the real-time PCR platforms LightCycler 480 II and cobas z 480Results from the test will help track the virus’ lineage closely and provide insights into the epidemiology and the impact it has on public health Concern from the World Health Organization centres around the high transmissibility and growth advantage of XBB.1.5 More information: Media Release, 26 January Collaborations Elecsys Amyloid Plasma PanelAlzheimer’s disease Collaboration with Lilly to enhance early diagnosis of Alzheimer’s disease Roche and Lilly will collaborate on the development of the Elecsys Amyloid Plasma PanelThe panel has demonstrated clinical performance and is currently undergoing additional investigation to ensure clinical validation Once approved, the panel could help healthcare professionals to streamline the journey to diagnosis for more patients More information: Media Release, 22 March Diagnostics sales Sales CHF millions As % of sales % change January–March 2023 2023 2022 2023 2022 At CER In CHF Diagnostics Division 3,623 5,286 100.0 100.0 -28 -31 Customer Areas3 Core Lab 1,928 1,896 53.1 35.9 7 2 Molecular Lab 593 1,189 16.4 22.5 -48 -50 Point of Care 397 1,466 11.0 27.7 -72 -73 Diabetes Care 376 417 10.4 7.9 -5 -10 Pathology Lab 329 318 9.1 6.0 7 3 Regions Europe, Middle East, Africa 1,253 1,902 34.6 35.9 -30 -34 North America 1,029 1,705 28.4 32.2 -39 -40 Asia-Pacific 1,098 1,395 30.3 26.5 -15 -21 Latin America 243 284 6.7 5.4 -8 -14 More information on Roche sales in the first quarter of 2023: Q1 2023 presentationAppendix with tables About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References[1] Unless otherwise stated, all growth rates and comparisons to the previous year in this document are at constant exchange rates (CER: average rates 2022) and all total figures quoted are reported in CHF.[2] Products launched before 2015.[3] Core Lab: diagnostics solutions in the areas of immunoassays, clinical chemistry and custom biotechPoint of Care: diagnostics solutions in emergency rooms, medical practices or directly with patients Molecular Lab: diagnostics solutions for pathogen detection and monitoring, donor screening, sexual health and genomicsDiabetes Care: integrated personalised diabetes management Pathology Lab: diagnostics solutions for tissue biopsies and companion diagnostics Cautionary statement regarding forward-looking statementsThis document contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, such as: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. Roche Group Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com Hans Trees, PhDPhone: +41 79 407 72 58 Nathalie AltermattPhone: +41 79 771 05 25 Karsten KleinePhone: +41 79 461 86 83 Nina MählitzPhone: +41 79 327 54 74 Dr. Barbara von SchnurbeinPhone: +41 79 699 97 44 Sileia Urech Phone: +41 79 935 81 48 Attachments Communications appendix tables_Q1 2023_Sales_v2 26042023_MR_Q1_Roche_en